Vasoconstrictive effect

The "vasoconstrictive effect" refers not to a single molecule or therapeutic target but rather a physiological process involving the narrowing of blood vessels through contraction of vascular smooth muscle cells. This process is regulated by numerous endogenous mediators—including norepinephrine acting on alpha-adrenoceptors, angiotensin II acting on its type I receptor, endothelins acting on their respective receptors, serotonin at certain subtypes—and can be modulated pharmacologically by various drugs. While essential for normal regulation of blood pressure and redistribution of circulation during stress responses, dysregulated vasoconstriction contributes significantly to pathologies such as hypertension and tissue ischemia. Because it describes an outcome rather than a discrete molecular entity or druggable target class, "vasoconstrictive effect" should not be considered a canonical therapeutic target itself but rather the result mediated by several well-defined molecular targets within the cardiovascular system.

Other names

Vasoconstrictive effectVasoconstriction

Mechanisms depend on the specific drug and target but commonly include: - Activation of alpha-adrenoceptors on vascular smooth muscle → contraction via increased intracellular calcium - Stimulation of angiotensin II type 1 receptors → Gq protein signaling → phospholipase C activation → IP3-mediated calcium release in smooth muscle cells - Activation of endothelin or urotensin II receptors leading to potent and sustained vasoconstriction via similar pathways - Inhibition or antagonism at these sites can block vasoconstrictive effects